Abstract
In developed countries, cardiovascular disease is one of the leading causes of death. Among other statins, pravastatin is abundantly prescribed to reduce risk of coronary artery disease by lowering cholesterol. Genetic factors are thought to be partly responsible for the interindividual variation in the response to pravastatin. This article reviews the most important studies conducted on the pharmacogenetics of pravastatin. Currently there is no evidence to advocate pharmacogenetic testing before initiating therapy
| Original language | English |
|---|---|
| Pages (from-to) | 1207-1210 |
| Journal | Pharmacogenomics |
| Volume | 9 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2008 |
| Externally published | Yes |